首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Lung Cancer

Lung Cancer杂志,由Elsevier Ireland Ltd出版,于1985年创刊,Monthly,出版语言English,ISSN:0169-5002,E-ISSN:1872-8332。

投稿咨询
Lung Cancer
Lung Cancer
Lung Cancer
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
2区
影响因子
5.3
CiteScore
7.4
期刊收录
SCI、SCIE

Lung Cancer(中文译名:《肺癌》),ISSN:0169-5002,EISSN:1872-8332,是Elsevier Ireland Ltd出版的国际性学术期刊,创刊于1985年,以Monthly形式稳定发行,2026年总发文量约320篇。该刊采用非OA开放访问,学科归属为医学 - 呼吸系统。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达5.3,2025年期刊CiteScore为7.4,2025年期刊自引率约3.8%,在中科院期刊分区体系中位列医学大类2区,在所属学科领域具备高学术影响力与国际认可度。Lung Cancer长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期一般,3-6周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,EnglandUSA、CHINA MAINLAND、Japan、Italy、France、GERMANY (FED REP GER)等为核心发文国家与地区;CHRISTIE NHS FOUNDATION TRUSTUNIVERSITY OF LONDON、UNIVERSITY OF MANCHESTER、ROYAL MARSDEN NHS FOUNDATION TRUST、UNICANCER、WYTHENSHAWE HOSPITAL NHS FOUNDATION TRUST、NATIONAL CANCER CENTER - JAPAN等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学 RESPIRATORY SYSTEM 呼吸系统
3区 2区
否 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学 RESPIRATORY SYSTEM 呼吸系统
3区 3区
否 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学 RESPIRATORY SYSTEM 呼吸系统
3区 3区
否 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 80 / 333

76.1

学科:RESPIRATORY SYSTEM SCIE Q1 16 / 107

85.5

学科:ONCOLOGY SCIE Q1 68 / 333

79.73

学科:RESPIRATORY SYSTEM SCIE Q1 21 / 107

80.84

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 85 / 328

74.2

学科:RESPIRATORY SYSTEM SCIE Q1 19 / 108

82.9

学科:ONCOLOGY SCIE Q1 69 / 328

79.12

学科:RESPIRATORY SYSTEM SCIE Q1 23 / 108

79.17


中国学者近期发文

1
First case report of transformation of adenocarcinoma to adenosquamous carcinoma with giant-cell carcinoma harboring HER2 mutation after zongertinib (BI 1810631) resistanc

Author:Lin, Jia-Xin; Yin, Kai; Yan, Li-Xu; Zhu, Yue; Xu, Bing-Fei; Sun, Yue-Li; Wu, Yi-Long; Tu, Hai-Yan

Journal: LUNG CANCER. 2026; Vol. 216, Issue , pp. -. DOI: 10.1016/j.lungcan.2026.108912

2
Surgery after neoadjuvant immunochemotherapy versus immuno-chemoradiotherapy in patients with cN3 non-small cell lung cancer: A cohort study in two academic center

Author:Zhai, Wenyu; Liang, Dachuan; Yu, Xiangyang; Dai, Shuqin; Guo, Xiaotong; Zhou, Yuheng; Yan, Qihang; Li, Liang; Yang, Jie; Wong, Wingshing; Gong, Li; Duan, Fangfang; Li, Xiaodong; Wang, Junye

Journal: LUNG CANCER. 2026; Vol. 216, Issue , pp. -. DOI: 10.1016/j.lungcan.2026.109409

3
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA tria

Author:Barlesi, Fabrice; Ahn, Jin Seok; Solomon, Benjamin J.; Nishio, Makoto; Dziadziuszko, Rafal; Lee, Dae Ho; Lee, Jong-Seok; Zhong, Wenzhao; Horinouchi, Hidehito; Mao, Weimin; Hochmair, Maximilian; de Marinis, Filippo; Migliorino, Maria Rita; Bondarenko, Igor; Xu, Tingting; Bara, Ilze; Ding, Beiying; Ngiam, Celina; Petric, Patricia; Wu, Yi-Long

Journal: LUNG CANCER. 2026; Vol. 216, Issue , pp. -. DOI: 10.1016/j.lungcan.2026.109385

4
Molecular subtyping of small-cell lung cancer in clinical practice: Primary tumor-lymph node concordance, intratumoral heterogeneity, and genomic context in a Chinese cohor

Author:Lin, Zhihong; Lyu, Qiong; Li, Jiawei; Fan, Lei; Wang, Ping; Wu, Yue; Lin, Xiaodong; He, Ping

Journal: LUNG CANCER. 2026; Vol. 215, Issue , pp. -. DOI: 10.1016/j.lungcan.2026.109377

5
Colony-stimulating factors improve neoadjuvant immunochemotherapy efficacy in non-small-cell lung cancer without EGFR or ALK mutations: A double-center real-world retrospective stud

Author:Huang, Yan; Lin, Xirui; Li, Zhichao; Fang, Caiyan; Chen, Jiyang; Xie, Xiuying; Wu, Hansheng; Wang, Weidong; Yang, Hong; Fu, Jianhua

Journal: LUNG CANCER. 2026; Vol. 215, Issue , pp. -. DOI: 10.1016/j.lungcan.2026.109380

6
Risk stratification in stage I invasive non-mucinous lung adenocarcinoma based on high-risk histopathologic feature

Author:Wang, Kai; Ding, Yun; Wang, Zixiao; Zhao, Yifan; Jiang, Yuhang; Mu, Qiuqiao; Gao, Guozheng; Wang, Jing; Zhang, Han; Li, Xin; Sun, Daqiang

Journal: LUNG CANCER. 2026; Vol. 215, Issue , pp. -. DOI: 10.1016/j.lungcan.2026.109388

7
Adjuvant immunotherapy may have no impact on survival in patients who received neoadjuvant immunotherapy for stage II-IIIB non-small cell lung cance

Author:Lin, Jun-Tao; Yang, Xue-Ning; Li, Xiang-Meng; Zhang, Chao; Nie, Qiang; Dong, Song; Jiang, Ben-Yuan; Liao, Ri-Qiang; Kang, Jing; Zhang, Jia-Tao; Yang, Jie; Zhang, Sheng; Hou, Jing-Yu; Fu, Rui; Chen, Zi-Hao; Qiu, Zhen-Bin; Yan, Hong-Hong; Wu, Yi-Long; Zhong, Wen-Zhao

Journal: LUNG CANCER. 2026; Vol. 215, Issue , pp. -. DOI: 10.1016/j.lungcan.2026.109389

8
Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohor

Author:Dong, Xiaorong; Jian, Hong; Huang, Meijuan; Yuan, Shuanghu; Zhu, Zhengfei; Wu, Lin; Chen, Ming; Bi, Nan; Pan, Yi; Wang, Yingyi; Lv, Dongqing; Monterroso, Elena Armenteros; Huang, Xiangning; Mao, Rui; Fu, Wei; Zhao, Yi; Lu, Shun

Journal: LUNG CANCER. 2026; Vol. 215, Issue , pp. -. DOI: 10.1016/j.lungcan.2026.109343

9
18F-FDG PET/CT and receptor-positive circulating tumor cells-based machine learning model for predicting poorly differentiated lung adenocarcinom

Author:Li, Yi; Zhang, Feng-Xian; Zhang, Wen-Long; Shen, Meng-Jun; Yi, Jia-Wei; Zhao, Qing-Qing; Zhao, Qing-Ping; Hao, Li-Yan; Qi, Jia-Jia; Li, Wan-Hu; Wu, Xiao-Dong; Zhao, Long; Wang, Yin

Journal: LUNG CANCER. 2026; Vol. 215, Issue , pp. -. DOI: 10.1016/j.lungcan.2026.109353

10
Hypermethylation of SHOX2 and RASSF1A in intraoperative pleural lavage fluid as a molecular signature of aggressive tumor biology and high histologic grade in stage I lung adenocarcinom

Author:Zhang, Yufei; Chen, Liang; Dai, Wenjun; Zhou, Yahui; Shi, Jianxin; Xu, Ye; Zhou, Wenyong

Journal: LUNG CANCER. 2026; Vol. 215, Issue , pp. -. DOI: 10.1016/j.lungcan.2026.109357


在线咨询

Lung Cancer

国际简称:LUNG CANCER参考译名:肺癌

年发文量:320 CiteScore:7.4 是否预警:否 Gold OA文章占比:30.75% 研究类文章占比:91.88%

杂志社联系方式:ELSEVIER IRELAND LTD, ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, IRELAND, 00000

Lung Cancer